Saturday 17 October 2026
Export INM’s income statement to Excel — free account
InMed Pharmaceuticals Inc.
INM Healthcare Drug Manufacturers Specialty & Generic
In the quarter to June 2026, revenue fell 26.2%, EPS fell 1,621.7%, free cash flow fell 40.4% and total debt fell 92.7%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
1.32
0.01
−0.75%
Follow INM
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
— | — | 3 | 4 |
+8 more TTM periods Free account |
| (179.09%) | (122.32%) | (97.20%) | (82.17%) | ||
| (139.63%) | (92.43%) | (77.83%) | (68.92%) | ||
ROIC |
0.00% | (244.94%) | (138.03%) | (156.22%) | |
Return on Tangible Assets |
(1,378.37%) | (159.97%) | (94.94%) | (81.09%) | |
Average Days of Receivables |
— | — | 11.58 | 20.69 | |
Free Cash Flow per Share |
(2.08) | (1.92) | (1.96) | (1.99) | |
Free Cash Flow |
(8.64) | (7.79) | (7.75) | (7.88) | |
| Other line items | |||||
Cash ROIC |
(261.20%) | (64.26%) | (46.41%) | (37.21%) | |
Accounts Receivable Turnover |
— | — | 25.89 | 19.29 | |
Accounts Payable Turnover |
0.00 | 0.00 | 3.48 | 3.99 | |
Inventory Turnover |
— | — | 4.15 | 4.04 | |
Average Days of Payables |
0.00 | 0.00 | 91.99 | 96.66 | |
Days of Inventory on Hand |
— | — | 81.35 | 76.18 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 42.27% | 44.60% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 92.85% | 90.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 1.95% | 1.82% | |
Operating CF/Net income |
0.67 | 0.92 | 1.01 | 0.96 | |
Depreciation/Fixed assets |
0.93 | 0.33 | 0.28 | 0.24 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 1.46 | 1.53 | |
Operating CF per Share |
(2.08) | (1.92) | (1.96) | (1.99) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
— | — | 0.00 | 0.00 |
Columns are period end dates